Details for New Drug Application (NDA): 080235

✉ Email this page to a colleague

NDA 080235 describes VASOCON, which is a drug marketed by Novartis and is included in two NDAs. Additional details are available on the VASOCON profile page.

The generic ingredient in VASOCON is antazoline phosphate; naphazoline hydrochloride. Additional details are available on the antazoline phosphate; naphazoline hydrochloride profile page.

Summary for 080235

Tradename:	VASOCON
Applicant:	Novartis
Ingredient:	naphazoline hydrochloride
Patents:	0

Medical Subject Heading (MeSH) Categories for 080235

Adrenergic alpha-Agonists
Nasal Decongestants

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION/DROPS;OPHTHALMIC			Strength	0.1%
Approval Date:	Mar 24, 1983	TE:		RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.